Not Signed In -
Citalopram |
Celexa; citalopram hydrobromide |
Clinical Trial: Antidepressant Treatment in Older Patients with Schizophrenia
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to evaluate the safety and effectiveness of citalopram (Celexa) for the treatment of depressive symptoms in middle-aged and elderly patients with schizophrenia.
| Condition | Treatment or Intervention |
|---|---|
| Schizophrenia | Drug: Citalopram (Celexa) |
MedlinePlus related topics: Schizophrenia
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Citalopram Augmentation in Older Patients with Schizophrenia
Expected Total Enrollment: 180
Study start: September 2001; Expected completion: August 2006
Older people with schizophrenia suffer from greater physical comorbidity, cognitive impairment, and medication side effects compared to their younger counterparts. Unfortunately, little research is available to guide the treatment of subsyndromal depressive symptoms in older adults. This study will compare the antidepressant citalopram to placebo to determine the most effective treatment for reducing depressive symptoms in older patients with schizophrenia
After patients have been on stable treatment with antipsychotic medication for at least 4 weeks, they are randomly assigned to receive antipsychotic medication plus either citalopram or placebo for 3 months. Depressive symptoms and side effects are assessed weekly for the first month, biweekly for the second month, and again at the end of the third month. Cognition, motor and daily functioning, quality of life, and medication adherence are assessed throughout the study.
Eligibility
Ages Eligible for Study: 40 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Schizophrenia or schizoaffective disorder
- HAM-D score of 8 or above
- Antipsychotic medication treatment
Location and Contact Information
California
San Diego VA Medical Center, San Diego, California, 92161, United States; Recruiting
Dilip V. Jeste, MD 858-534-4020 djeste@ucsd.edu
Sidney Zisook, MD, Principal Investigator
Ohio
Veterans Administration Hospital of Cincinnati, Cincinnati, Ohio, 45220, United States; Recruiting
Somaia Mohamed, M.D.; Ph. D. 513-861-3100 Ext. 4880 somaia.mohamed@med.va.gov
John W Kasckow, MD; PhD, Principal Investigator
Sidney Zisook, MD, Principal Investigator, University of California, San Diego
More Information
UCSD Geropsychiatry Advanced Clinical Intervention And Services Research Center
Record last reviewed: March 2005
Last Updated: March 24, 2005
Record first received: October 4, 2002
ClinicalTrials.gov Identifier: NCT00047450
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- Celexa (Drug Digest)
- Celexa Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
